logo
Plus   Neg
Share
Email

Dynasil Corp. Of America (DYSL) Has Surged To A New High

Dynasil Corp. Of America (DYSL) announced Wednesday morning that its Xcede Technologies subsidiary has completed most of the required ISO 10993-1 Testing Program for the Xcede Hemostatic Patch. The company is encouraged by the results thus far and expects to start clinical trials in the Netherlands in early 2018.

Dynasil has been rising steadily since the open of trade Wednesday and is now up 0.51 at $1.73 on the highest volume of the year. The stock has surged to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT